548. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 315 of 11 February 2025, and noting that the National Centre for Pharmacoeconomics completed a full health technology assessment of tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus on 9 February 2026, and for weight management on 3 December 2025, whether she has been notified of the completion of those assessments; the month in 2026 in which the HSE senior leadership team is scheduled to consider each application for pricing and reimbursement; whether any internal target decision date has been set by her Department or the HSE; and if she will make a statement on the matter. [15874/26]

Summary

548. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 315 of 11 February 2025, and noting that the National Centre for Pharmacoeconomics completed a full health technology assessment of tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus on 9 February 2026, and for weight management on 3 December 2025, whether she has been notified of the completion of those assessments; the month in 2026 in which the HSE senior leadership team is scheduled to consider each application for pricing and reimbursement; whether any internal target decision date has been set by her Department or the HSE; and if she will make a statement on the matter. [15874/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 26 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.